Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice.

BACKGROUND The role of plasminogen system components in focal cerebral ischemic infarction (FCI) was studied in mice deficient in plasminogen (Plg-/-), in tissue or urokinase plasminogen activator (tPA-/- or uPA-/-), or in plasminogen activator inhibitor-1 or alpha2-antiplasmin (PAI-1(-/-) or alpha2-AP-/-). METHODS AND RESULTS FCI was produced by ligation of the left middle cerebral artery and measured after 24 hours by planimetry of stained brain slices. In control (wild-type) mice, infarct size was 7.6+/-1.1 mm3 (mean+/-SEM), uPA-/- mice had similar infarcts (7.8+/-1.0 mm3, P=NS), tPA-/- mice smaller (2.6+/-0.80 mm3, P<0.0001), PAI-1(-/-) mice larger (16+/-0.52 mm3, P<0.0001), and Plg-/- mice larger (12+/-1.2 mm3, P=0.037) infarcts. alpha2-AP-/- mice had smaller infarcts (2. 2+/-1.1 mm3, P<0.0001 versus wild-type), which increased to 13+/-2.5 mm3 (P<0.005 versus alpha2-AP-/-) after intravenous injection of human alpha2-AP. Injection into alpha2-AP-/- mice of Fab fragments of affinospecific rabbit IgG against human alpha2-AP, after injection of 200 microg human alpha2-AP, reduced FCI from 11+/-1.5 to 5.1+/-1.1 mm3 (P=0.004). CONCLUSIONS Plg system components affect FCI at 2 different levels: (1) reduction of tPA activity (tPA gene inactivation) reduces whereas its augmentation (PAI-1 gene inactivation) increases infarct size, and (2) reduction of Plg activity (Plg gene inactivation or alpha2-AP injection) increases whereas its augmentation (alpha2-AP gene inactivation or alpha2-AP neutralization) reduces infarct size. Inhibition of alpha2-AP may constitute a potential avenue to treatment of FCI.

[1]  E. Connolly,et al.  Procedural and strain-related variables significantly affect outcome in a murine model of focal cerebral ischemia. , 1996, Neurosurgery.

[2]  S. Strickland,et al.  Neuronal Death in the Hippocampus Is Promoted by Plasmin-Catalyzed Degradation of Laminin , 1997, Cell.

[3]  T. Sakamoto,et al.  Effect of Lactacidosis on Pyridine Nucleotide Stability During Ischemia in Mouse Brain , 1987, Journal of neurochemistry.

[4]  S. Tsirka,et al.  An Extracellular Proteolytic Cascade Promotes Neuronal Degeneration in the Mouse Hippocampus , 1997, The Journal of Neuroscience.

[5]  D. Collen,et al.  Alpha2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding. , 1999, Blood.

[6]  P. Carmeliet,et al.  Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. , 1993, The Journal of clinical investigation.

[7]  A. Giles,et al.  Guidelines for the use of Animals in Biomedical Research , 1987, Thrombosis and Haemostasis.

[8]  P. Carmeliet,et al.  Adenovirus-Mediated Transfer of Tissue-Type Plasminogen Activator Augments Thrombolysis in Tissue-Type Plasminogen Activator–Deficient and Plasminogen Activator Inhibitor-1–Overexpressing Mice , 1997 .

[9]  P. Carmeliet,et al.  Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. , 1997, Circulation.

[10]  P. Carmeliet,et al.  Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. , 1995, Circulation.

[11]  F. Graham,et al.  A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. , 1988, Virology.

[12]  J. Coyle,et al.  Oxidative stress, glutamate, and neurodegenerative disorders. , 1993, Science.

[13]  P. Carmeliet,et al.  Generation of Monoclonal Antibodies against Autologous Proteins in Gene-inactivated Mice (*) , 1995, The Journal of Biological Chemistry.

[14]  H. Wada,et al.  Origin of patterning in neural tubes , 1996, Nature.

[15]  B. Wiman,et al.  Amino‐acid sequence of human α2‐antiplasmin , 1987 .

[16]  B. Wiman,et al.  Turnover of antiplasmin, the fast-acting plasmin inhibitor of plasma. , 1979, Blood.

[17]  S. Tsirka,et al.  Neuronal cell death and tPA , 1996, Nature.

[18]  Sidney Strickland,et al.  Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator , 1995, Nature.

[19]  P. Carmeliet,et al.  Physiological consequences of loss of plasminogen activator gene function in mice , 1994, Nature.

[20]  P. Carmeliet,et al.  Generation and characterization of urokinase receptor-deficient mice. , 1996, The Journal of clinical investigation.

[21]  P. Carmeliet,et al.  Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. , 1993, The Journal of clinical investigation.

[22]  J. Coyle,et al.  In situ injection of kainic acid: A new method for selectively lesioning neuronal cell bodies while sparing axons of passage , 1978, The Journal of comparative neurology.

[23]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[24]  P. Carmeliet,et al.  Generation of monoclonal antibodies against autologous proteins in gene-inactivated mice , 1994 .

[25]  C. Mendelson,et al.  Genomic elements involved in transcriptional regulation of the rabbit surfactant protein-A gene. , 1993, Molecular endocrinology.

[26]  L. Pitts,et al.  Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. , 1986, Stroke.

[27]  B. Wiman,et al.  Amino-acid sequence of human a2-antiplasmin , 1987 .

[28]  F. Graham,et al.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5. , 1977, The Journal of general virology.

[29]  Koroshetz Wj,et al.  Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.

[30]  S. Lipton,et al.  Tissue plasminogen activator (tPA) increase neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice , 1998, Nature Medicine.

[31]  S. Lipton,et al.  Excitatory amino acids as a final common pathway for neurologic disorders. , 1994, The New England journal of medicine.

[32]  D. Collen,et al.  Intravenous thrombolysis with recombinant staphylokinase versus tissue-type plasminogen activator in a rabbit embolic stroke model. , 1997, Stroke.

[33]  R. Ratcheson.  Meeting the challenges to neurosurgical education. , 1986, Clinical neurosurgery.

[34]  C. Newgard,et al.  Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen metabolism. , 1992, The Journal of biological chemistry.

[35]  J. Willard,et al.  Adenovirus‐Mediated Transfer of a Gene Encoding Human Apolipoprotein A‐I Into Normal Mice Increases Circulating High‐Density Lipoprotein Cholesterol , 1994, Circulation.

[36]  M. Kaste,et al.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.